The FDA has granted Topotarget Accelerated Approval of Beleodaq (belinostat), from BioAlliance Pharma, for the treatment of patients with relapsed...
Spectrum Pharmaceuticals has announced that its New Drug Application (NDA) for Beleodaq (belinostat), a novel, pan-histone deacetylase (HDAC) inhibitor, has...